Study of the Safety, Tolerability and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine (IN) for Postoperative Pain

Inclusion Criteria: * Men or women, age 18 years or older * Body weight \> or = 100 pounds (45.4 kg) and \< or = 300 pounds (136.1 kg) * Women of childbearing potential must have had a negative serum pregnancy test result prior to entry into the study * Able to provide written informed consent * At least moderate pain as determined by a PI score of \> or = 40 mm on a 100-mm VAS * Expected to remain in the hospital for at least 48 hours * Willing and able to comply with all testing and requirements defined in the protocol * Willing and able to complete the posttreatment visit Exclusion Criteria: * Allergy or sensitivity to ketorolac or ethylene diamine tetraacetic acid (EDTA) * Allergic reaction to aspirin or other nonsteroidal anti-inflammatory drug (NSAIDs) * Current upper respiratory tract infection or other respiratory tract condition that could interfere with the absorption of the nasal spray or with the assessment of adverse events * Use of any IN product within 24 hours prior to study entry * Clinically significant abnormality on screening laboratory tests * History of cocaine use resulting in nasal mucosal damage * Active peptic ulcer disease, recent (defined as within 6 months) gastrointestinal bleeding or perforation, or a history of peptic ulcer disease or gastrointestinal bleeding * Advanced renal impairment or a risk for renal failure due to volume depletion * A history of any other clinically significant medical problem, which in the opinion of the investigator would interfere with study participation * Participation within 30 days of study entry or within 5 times the half-life, whichever is longer, in another investigational drug study * Allergy or significant reaction to opioids * Pregnancy or breastfeeding * Previous participation in this study